Core Viewpoint - Xinhua Medical (600587) plans to invest 60 million yuan of its own funds into its wholly-owned subsidiary, Xinhua Medical Rehabilitation Industry (Xi'an) Co., Ltd., to enhance its operational capacity and development capabilities [1] Group 1: Investment Details - The investment aims to supplement the working capital of the Xi'an Rehabilitation Company [1] - The funding will accelerate the research, production, and sales processes of rehabilitation equipment [1] - The company has established a solid industrial foundation through professional technical accumulation and precise market positioning [1] Group 2: Company Progress - Xinhua Medical Rehabilitation Company has made good progress in research and development, production, and sales [1] - The investment is intended to further expand the company's scale [1]

Core Viewpoint - The successful completion of the first cross-border digital payment using digital RMB in Laos marks a significant advancement in the bilateral digital payment cooperation between China and Laos, showcasing the practical application of digital RMB for Chinese residents abroad [1][4]. Group 1: Digital RMB Implementation - The first transaction involved a Chinese tourist making a payment of 3,000 LAK (approximately 0.99 CNY) at a merchant in Laos using the digital RMB app, eliminating the need for currency exchange [2][3]. - The transaction was processed through the Ant Group's subsidiary, MyBank, which is one of the first institutions to operate digital RMB [3]. Group 2: Bilateral Cooperation Framework - In 2024, the People's Bank of China and the Bank of the Lao People's Democratic Republic signed a memorandum to enhance cooperation on digital payments and central bank digital currencies [4]. - The first phase of the bilateral cross-border digital payment cooperation project began in December 2025, focusing on the interconnection of digital RMB payment platforms with Laos' national payment network (LAPNet) [4]. - The project aims to facilitate the use of digital RMB for cross-border trade and payments, with future phases planned to support Lao residents using their digital wallets in China [4]. Group 3: Strategic Alignment - The initiative aligns with China's broader strategy to enhance the international use of the RMB and support regional economic cooperation, particularly in Southeast Asia [3][4]. - The successful implementation of the digital RMB in Laos is expected to expand its cross-border application and explore cost-effective methods for cross-border payments [3].

1月5日上午消息，1月4日晚，大麦网浙江站官方微博发布关于"2026十个勤天后陡门新春见面会"票务公 告。公告称，因平台工作人员配置失误，致使本应于2026年1月4日20：56开售的"2026十个勤天后陡门新 春见面会-鹭卓专场"演出售票通道于20：29被工作人员误触开启，对此，我们向鹭卓先生及其团队、主办 方、所有受到影响的粉丝、消费者致以最诚挚的歉意。 大麦方面表示，为保障全体观众的公平购票权益，针对提前销售的全部门票，平台将统一按退款退票处 理，票款将于7个工作日内原路退回。于20：56后抢票用户不受本次退票影响。后续退票将再次全部重新 开售，相关补偿、后续安排及因本次失误造成的排队规则可能产生的变动均将于确认后第一时间通过官方 渠道告知。 随后，大麦官博也发声称，"向鹭卓先生及其团队、主办方、所有受到影响的粉丝、消费者致以最诚挚的 歉意。 后续安排确认后将第一时间通过官方渠道告知。" 1月4日晚，"鹭卓后陡门新春见面会"在20点56分开启售票，有用户发文称大麦平台在售票过程中提前放 票，引发网友不满。 ...

批复显示，保定银行应根据《中国银保监会中资商业银行行政许可事项实施办法》（中国银保监会令 2022年第5号）等有关规定，加强对股东资质审核。同时应严格审查入股资金来源，投资人入股资金必 须为自有资金，且确保资金来源合法，不得以委托资金、债务资金等非自有资金入股。保定银行应严格 遵照有关法律法规完成变更事宜，完成变更后及时向我局提出变更注册资本申请。 1月4日，国家金融监督管理总局河北监管局发布批复，同意保定银行变更注册资本方案，募集股份2.5 亿股。 ...

1月4日，国家金融监督管理总局新疆监管局发布批复，同意新疆银行注册资本由人民币79.06亿元变更为122.23亿元。 ...

批复显示，北银消金应按照有关规定及时办理变更事宜，同时你公司应加强股权管理，严格控制股东关 联交易，完善公司治理与内部控制机制，防范和化解风险。 1月4日，国家金融监督管理总局北京监管局发布批复，同意北银消费金融有限公司增加注册资本1.5亿 元人民币，注册资本由8.5亿元人民币变更为10亿元人民币。 ...

Core Viewpoint - The National Financial Supervision Administration's Beijing Regulatory Bureau has approved China United Insurance Company to publicly issue 10-year redeemable capital supplement bonds with a maximum issuance scale of RMB 5.7 billion [1] Group 1: Issuance Details - China United Insurance is authorized to issue capital supplement bonds in the national interbank bond market [1] - The issuance scale is capped at RMB 5.7 billion, which includes the entire amount [1] - The company must comply with relevant regulations, including the announcement by the People's Bank of China and the China Insurance Regulatory Commission regarding insurance companies issuing capital supplement bonds [1] Group 2: Compliance and Reporting - China United Insurance is required to complete the issuance within the timeframe set by the bond market regulatory authority [1] - The company must report the issuance status to the Beijing Financial Regulatory Bureau within 10 working days after the issuance concludes [1]

1月4日，索菲亚发布公告，公司于2026年1月4日召开第六届董事会第七次会议，审议通过了《关于增加 董事会席位暨选举非独立董事的议案》。经公司独立董事专门委员会审核，董事会同意公司股东宁波盈 峰睿和投资管理有限公司（以下简称"宁波睿和"）及其一致行动人盈峰集团有限公司提名李力为公司第 六届董事会非独立董事会候选人，并提交股东会审议，任期自股东会审议通过之日起至公司第六届董事 会任期届满之日止。 ...

Core Viewpoint - Shanxi Meitehao Chain Supermarket Co., Ltd. is undergoing a restructuring process to address operational issues, with a focus on protecting the rights and interests of all parties involved [1] Group 1: Restructuring and Management - The restructuring work group has entrusted Shen Nong Investment (Shanxi) Co., Ltd. to manage the operations of Meitehao [1] - From January 4, 2026, several stores including Kaixuan Street, Jian Caoping, Sports Road, Kangning Street, and Kaixin Daji Binhai will undergo business restructuring [1] - The first batch of 15 stores will reopen on January 25, with other stores to follow based on the preparation plan [1] Group 2: Employee and Customer Considerations - The stores that reopen will prioritize the employment of original staff members [1] - Meitehao's stored value cards will continue to be valid, with usage guidelines to be announced by January 12 [1] Group 3: Stakeholder Rights - The legal rights of financial institutions, suppliers, and other relevant parties will be handled in accordance with the law [1] - A dedicated reception area and phone line have been established to facilitate comprehensive support for the restructuring process [1]

Core Viewpoint - Recently, Sunshine Nuohuo announced that it received a first-instance judgment from the Intermediate People's Court of Hengyang City, Hunan Province, ordering Hengsheng Pharmaceutical Co., Ltd. to pay overdue research and development fees totaling 2.15 million yuan and corresponding late payment penalties [1] Group 1: Legal Proceedings - The court ruled that Hengsheng Pharmaceutical must pay Sunshine Nuohuo a total of 2.15 million yuan for overdue R&D fees [1] - Sunshine Nuohuo has filed a lawsuit against Hengsheng Pharmaceutical regarding overdue R&D fees for a total of 24 products, including "Aminobromide Hydrochloride Injection (2ml: 15mg)" and "Clindamycin Phosphate Injection (2ml: 0.3g, 4ml: 0.6g)" [1]